Printed From:

FOR US RESIDENTS ONLY
Important Safety Information Prescribing Information Patient Information US Healthcare Professionals Site
Important Safety Information Prescribing Information Patient Information US Healthcare Professionals Site
  • Home
  • About
    SARCLISA
    • How SARCLISA Works
    • Clinical Study Results
    • Possible Side Effects
    • Considering SARCLISA
    • FAQs
  • SARCLISA
    Treatment
    Schedule
  • Paying for
    SARCLISA
  • Resources
    and Support
    • For Patients
    • For Caregivers
  • When Multiple
    Myeloma Returns

Site Map

About SARCLISA

  • How SARCLISA Works
  • Clinical Study Results
  • Possible Side Effects
  • Considering SARCLISA
  • Frequently Asked Questions

SARCLISA Treatment Schedule

Paying for SARCLISA

Resources and Support

  • For Patients
  • For Caregivers

When Multiple Myeloma Returns

Go Home

Email a link to this page

Your friend has shared this page about highs and lows

send to another
Your email has been sent

Your email has been sent to:

Important Safety Information

Do not receive SARCLISA if you have a history of severe allergic reaction to isatuximab-irfc or any of the ingredients in SARCLISA (see the list of ingredients in full Prescribing Information).

Before receiving SARCLISA, tell your healthcare provider about all of your medical conditions, including if you:

  • are pregnant or plan to become pregnant. SARCLISA may harm your unborn baby. You should not receive SARCLISA during pregnancy.
    • — Females who are able to become pregnant should use an effective method of birth control during treatment and for 5 months after their last dose of SARCLISA. Talk to your healthcare provider about birth control methods that you can use during this time.

    Tell your healthcare provider right away if you think you are pregnant or become pregnant during treatment with SARCLISA.

  • are breastfeeding or plan to breastfeed. It is not known if SARCLISA passes into your breast milk. You should not breastfeed during treatment with SARCLISA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive SARCLISA?

  • SARCLISA will be given to you by your healthcare provider by intravenous (IV) infusion into your vein.
  • SARCLISA is given in treatment cycles of 28 days (4 weeks), together with the medicines pomalidomide and dexamethasone.
    • — In cycle 1, SARCLISA is usually given weekly.
    • — Starting in cycle 2, SARCLISA is usually given every 2 weeks.

    Your healthcare provider will decide how long you should receive SARCLISA.

  • If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.
  • Your healthcare provider will give you medicines before each dose of SARCLISA to help reduce the risk of infusion reactions (make them less frequent and severe).

What are the possible side effects of SARCLISA?

SARCLISA may cause serious side effects, including:

  • Infusion reactions. Infusion reactions are common with SARCLISA and can sometimes be severe.

    • — Your healthcare provider will prescribe medicines before each infusion of SARCLISA to help decrease your risk for infusion reactions or to help make any infusion reaction less severe. You will be monitored for infusion reactions during each dose of SARCLISA.
    • — Your healthcare provider may slow down or stop your infusion, or completely stop treatment with SARCLISA, if you have an infusion reaction.

    Tell your healthcare provider right away if you develop any of the following symptoms of infusion reaction during or within 24 hours after an infusion of SARCLISA:

    • — feeling short of breath
    • — cough
    • — chills
    • — nausea

  • Decreased white blood cell counts. Decreased white blood cell counts are common with SARCLISA and certain white blood cells can be severely decreased. You may have an increased risk of getting certain infections, such as upper and lower respiratory infections.

    Your healthcare provider will check your blood cell counts during treatment with SARCLISA. Your healthcare provider may prescribe an antibiotic or antiviral medicine to help prevent infection, or a medicine to help increase your white blood cell counts during treatment with SARCLISA.

    • Tell your healthcare provider right away if you develop any fever or symptoms of infection during treatment with SARCLISA.

  • Risk of new cancers. New cancers have happened in people during treatment with SARCLISA. Your healthcare provider will monitor you for new cancers during treatment with SARCLISA.

  • Change in blood tests. SARCLISA can affect the results of blood tests to match your blood type. Your healthcare provider will do blood tests to match your blood type before you start treatment with SARCLISA. Tell all of your healthcare providers that you are being treated with SARCLISA before receiving blood transfusions.

The most common side effects of SARCLISA include:

  • lung infection (pneumonia)
  • decreased red blood cell counts (anemia)
  • upper respiratory tract infection
  • decreased platelet counts (thrombocytopenia)
  • diarrhea

These are not all the possible side effects of SARCLISA. For more information, ask your healthcare provider or pharmacist.

Please see full Prescribing Information, including Patient Information.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

What is SARCLISA?

SARCLISA is a prescription medicine used in combination with pomalidomide and dexamethasone to treat adults who have received at least 2 prior therapies, including lenalidomide and a proteasome inhibitor, to treat multiple myeloma.

It is not known if SARCLISA is safe and effective in children.

Please see full Prescribing Information, including Patient Information.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

Kyprolis is a registered trademark of Amgen, Inc.
Ninlaro and Velcade are registered trademarks of Millennium Pharmaceuticals, Inc.
Pomalyst and Revlimid are registered trademarks of Celgene Corporation.

Pomalyst is a registered trademark of Celgene Corporation.

Important Safety Information

Do not receive SARCLISA if you have a history of severe allergic reaction to isatuximab-irfc or any of the ingredients in SARCLISA (see the list of ingredients in full Prescribing Information).

Before receiving SARCLISA, tell your healthcare provider about all of your medical conditions, including if you:

  • are pregnant or plan to become pregnant. SARCLISA may harm your unborn baby. You should not receive SARCLISA during pregnancy.
    • — Females who are able to become pregnant should use an effective method of birth control during treatment and for 5 months after their last dose of SARCLISA. Talk to your healthcare provider about birth control methods that you can use during this time.

    Tell your healthcare provider right away if you think you are pregnant or become pregnant during treatment with SARCLISA.

  • are breastfeeding or plan to breastfeed. It is not known if SARCLISA passes into your breast milk. You should not breastfeed during treatment with SARCLISA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive SARCLISA?

  • SARCLISA will be given to you by your healthcare provider by intravenous (IV) infusion into your vein.
  • SARCLISA is given in treatment cycles of 28 days (4 weeks), together with the medicines pomalidomide and dexamethasone.
    • — In cycle 1, SARCLISA is usually given weekly.
    • — Starting in cycle 2, SARCLISA is usually given every 2 weeks.

    Your healthcare provider will decide how long you should receive SARCLISA.

  • If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.
  • Your healthcare provider will give you medicines before each dose of SARCLISA to help reduce the risk of infusion reactions (make them less frequent and severe).

What are the possible side effects of SARCLISA?

SARCLISA may cause serious side effects, including:

  • Infusion reactions. Infusion reactions are common with SARCLISA and can sometimes be severe.

    • — Your healthcare provider will prescribe medicines before each infusion of SARCLISA to help decrease your risk for infusion reactions or to help make any infusion reaction less severe. You will be monitored for infusion reactions during each dose of SARCLISA.
    • — Your healthcare provider may slow down or stop your infusion, or completely stop treatment with SARCLISA, if you have an infusion reaction.

    Tell your healthcare provider right away if you develop any of the following symptoms of infusion reaction during or within 24 hours after an infusion of SARCLISA:

    • — feeling short of breath
    • — cough
    • — chills
    • — nausea

  • Decreased white blood cell counts. Decreased white blood cell counts are common with SARCLISA and certain white blood cells can be severely decreased. You may have an increased risk of getting certain infections, such as upper and lower respiratory infections.

    Your healthcare provider will check your blood cell counts during treatment with SARCLISA. Your healthcare provider may prescribe an antibiotic or antiviral medicine to help prevent infection, or a medicine to help increase your white blood cell counts during treatment with SARCLISA.

    • Tell your healthcare provider right away if you develop any fever or symptoms of infection during treatment with SARCLISA.

  • Risk of new cancers. New cancers have happened in people during treatment with SARCLISA. Your healthcare provider will monitor you for new cancers during treatment with SARCLISA.

  • Change in blood tests. SARCLISA can affect the results of blood tests to match your blood type. Your healthcare provider will do blood tests to match your blood type before you start treatment with SARCLISA. Tell all of your healthcare providers that you are being treated with SARCLISA before receiving blood transfusions.

The most common side effects of SARCLISA include:

  • lung infection (pneumonia)
  • decreased red blood cell counts (anemia)
  • upper respiratory tract infection
  • decreased platelet counts (thrombocytopenia)
  • diarrhea

These are not all the possible side effects of SARCLISA. For more information, ask your healthcare provider or pharmacist.

Please see full Prescribing Information, including Patient Information.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

What is SARCLISA?

SARCLISA is a prescription medicine used in combination with pomalidomide and dexamethasone to treat adults who have received at least 2 prior therapies, including lenalidomide and a proteasome inhibitor, to treat multiple myeloma.

It is not known if SARCLISA is safe and effective in children.

Please see full Prescribing Information, including Patient Information.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

Kyprolis is a registered trademark of Amgen, Inc.
Ninlaro and Velcade are registered trademarks of Millennium Pharmaceuticals, Inc.
Pomalyst and Revlimid are registered trademarks of Celgene Corporation.

Pomalyst is a registered trademark of Celgene Corporation.





MAT-US-2001674 :
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Site Map

This site is intended for US residents only.

© 2020 sanofi-aventis U.S. LLC.
All rights reserved.
MAT-US-2001674 Last Updated: 08/20

Sanofi Genzyme logo

This information is intended for US Healthcare Professionals only.

Select the “Continue” button below to go to the page you requested, or the “Cancel” button to return to the previous page.

You are about to leave SARCLISA.com.

Sanofi Genzyme does not review or control the content of non–Sanofi Genzyme websites, and this hyperlink does not constitute an endorsement by Sanofi Genzyme of the site's content. Sanofi Genzyme's privacy procedures do not apply to the owners of a non–Sanofi Genzyme website.

You are about to leave sanofi site for U.S.

Sanofi US does not review the information contained on this website and/or database for content, accuracy or completeness. Use of and access to this information is subject to the terms, limitations and conditions set by the website and/or database producer.

This site might not comply with the regulatory requirements of US

You are about to move to an Unbranded site

You are moving to an Unbranded site